ERBB2 and breast carcinoma: A study from 2010 revealed a significant association between Beclin1 deletion and human epidermal growth factor receptor 2 (ErbB2) amplification [119], thus providing evidence for decreased Beclin1 expression in a particular breast cancer subtype [120].